-- Israel Stocks: Protalix, Biocell, Ceragon, Delta-Galil, Medigus
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-05-02T14:06:05Z
-- http://www.bloomberg.com/news/2012-05-02/israel-stocks-protalix-biocell-ceragon-delta-galil-medigus.html
Israel ’s  TA-25 index  slid to its
lowest in more than a week, declining 0.7 percent to 1,158.65 at
the 4:30 p.m. close in  Tel Aviv . Investors traded about 1
billion shekels ($264 million) of shares and convertible
securities, according to bourse data.  The following stocks rose or fell today. Symbols are in
parentheses.  Can-Fite Biopharma Ltd. (CFBI)   dropped 3.9 percent to
0.394 shekel, the lowest level since April 18. The Petach Tikva,
Israel-based biopharmaceutical company raised about 5.8 million
shekels from a public offering of securities.  Ceragon Networks Ltd. (CRNT)   advanced 1.9 percent to
35.97 shekels, the highest close since April 18. The maker of
wireless-networking systems won orders for high-capacity
wireless products from the Florida Rural Broadband Alliance.  Delta-Galil Industries Ltd. (DELT)   advanced 6 percent to
32.62 shekels, the highest since January 2011. The manufacturer
of intimate apparel signed an accord to buy Schiesser Group AG
for 68 million euros ($89 million).  Intec Pharma Ltd. (INTP)   retreated 4.9 percent, the most
since Dec. 27, to 0.982 shekel giving the company a market value
of 181 million shekels. The drug developer plans to raise 15
million shekels via a rights offering.  Medigus Ltd. (MDGS)   gained 3.5 percent, the most since
April 30, to 1.063 shekels. The developer of endoscopic
procedures and devices expects a decision in the “near future”
by the U.S. Food and Drug Administration on an application to
market its SRS device to treat gastroesophageal-reflux disease.  Protalix BioTherapeutics Inc. (PLX)   surged 14 percent to
29.14 shekels, the highest since February 2011. The
biopharmaceutical company’s debut drug won approval from the
U.S. Food and Drug Administration.  Biocell Ltd. (BCEL)  ,
Protalix’s largest shareholder, jumped the most since January
2009, advancing 26 percent to 34.87 shekels.  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  